GlassScriptPhysician profile
Michael Waters
NPI 1811965908
$5,263.99
in general payments reported to CMS, 2019-2025
41 companies · $769 in 2025
The $769 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,020 · 2020: $699 · 2021: $204 · 2022: $166 · 2023: $608 · 2024: $798 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $849.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $824.91 | 2019-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $692.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $326.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $210.27 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $207.35 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.66 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $168.48 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $145.67 | 2019-2020 | |
| Abbvie INC. | $119.01 | 2019-2025 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $113.87 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $109.32 | 2019-2025 | Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $105.14 | 2019-2023 | Veozah |
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $79.49 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.